



HIGH GLUCOSE EXPOSURE PROMOTES PROLIFERATION AND IN VIVO NETWORK FORMATION OF ADIPOSE-TISSUE-DERIVED MICROVASCULAR FRAGMENTS

M.W. Laschke^{1,*}, M.S. Seifert¹, C. Scheuer¹, E. Kontaxi¹, W. Metzger² and M.D. Menger¹

¹Institute for Clinical and Experimental Surgery, Saarland University, 66421 Homburg/Saar, Germany ²Department of Trauma, Hand and Reconstructive Surgery, Saarland University, 66421 Homburg/Saar, Germany

Abstract

High glucose concentrations have been shown to activate endothelial cells and promote angiogenesis. In the present study, it was investigated whether high glucose concentrations could improve the vascularisation capacity of adipose-tissue-derived microvascular fragments (ad-MVF). Ad-MVF were isolated from the epididymal fat pads of donor mice and cultivated for 24 h in University of Wisconsin (UW) solution supplemented with vehicle or 30 mM glucose. Protein expression, morphology, viability and proliferation of the cultivated ad-MVF were analysed by means of proteome profiler mouse angiogenesis array, scanning electron microscopy and immunohistochemistry. Additional cultivated ad-MVF were seeded on to collagenglycosaminoglycan scaffolds to study their in vivo vascularisation capacity in the dorsal skinfold chamber model by intravital fluorescence microscopy, histology and immunohistochemistry. In vitro, high glucose exposure changed the protein expression pattern of ad-MVF with endoglin, interleukin (IL)-1 β and monocyte chemoattractant protein (MCP)-1 as the most up-regulated pro-angiogenic factors. Moreover, high glucose exposure induced the formation of nanopores in the ad-MVF wall. In addition, ad-MVF contained significantly larger numbers of proliferating endothelial and perivascular cells while exhibiting a comparable number of apoptotic cells when compared to vehicle-treated controls. In vivo, scaffolds seeded with high-glucose-exposed ad-MVF exhibited an improved vascularisation and tissue incorporation. These findings demonstrated that the exposure of cultivated ad-MVF to high glucose concentrations is a promising approach to improve their in vivo performance as vascularisation units for tissue engineering and regenerative medicine.

Keywords: Tissue engineering, microvascular fragments, glucose, hyperglycaemia, angiogenesis, vascularisation, scaffold.

*Address for correspondence: Matthias W. Laschke, MD, PhD, Institute for Clinical and Experimental Surgery, Saarland University, D-66421 Homburg/Saar, Germany. Telephone number: +49 68411626554 Fax number: +49 68411626553 Email: matthias.laschke@uks.eu

Copyright policy: This article is distributed in accordance with Creative Commons Attribution Licence (http://creativecommons.org/licenses/by-sa/4.0/).

Introduction

Adipose-tissue-derived microvascular fragments (ad-MVF) are arteriolar, capillary and venular vessel segments, which are isolated by short-term enzymatic digestion of fat samples (Laschke and Menger, 2015). Originally, these vessel segments have been used in physiology and angiogenesis research to study endothelial transport processes (Williams *et al.*, 1981), interaction of endothelial cells with extracellular matrix compounds (Madri *et al.*, 1983) or effects of cytokines and growth factors on microvascular network formation (Sato *et al.*, 1990; Sato *et al.*, 1993). More recently, ad-MVF have

been incorporated into different scaffold materials to improve the vascularisation of implanted tissue constructs, such as epicardial patches (Shepherd *et al.*, 2007) or bone and dermal skin substitutes (Frueh *et al.*, 2017a; Laschke *et al.*, 2012).

Ad-MVF bear several unique advantages, which make them attractive vascularisation units for tissue engineering and regenerative medicine. They can be isolated in large amounts quickly from fat samples (Frueh *et al.*, 2017b). Due to their preserved vessel architecture and functionality after isolation, they rapidly reassemble into new blood-perfused microvascular networks after *in vivo* implantation (Später *et al.*, 2018). Moreover, they contain mesenchymal stem cells within their physiological niche, which exhibit a high capacity for angiogenic, neurogenic, adipogenic and osteogenic differentiation (McDaniel *et al.*, 2014). In addition, ad-MVFs can be pre-cultivated for up to 24 h prior to their *in vivo* application without losing their physiological vessel morphology (Laschke *et al.*, 2019a). This offers the possibility of further improving their angiogenic activity by exposing them to different physical and biochemical stimuli, such as subnormothermic temperatures and pro-angiogenic factors (Karschnia *et al.*, 2018; Laschke *et al.*, 2019a; Laschke *et al.*, 2019b).

The study hypothesis was that the *in vitro* exposure of cultivated ad-MVF to high glucose concentrations increases their *in vivo* microvascular-networkforming capacity. This assumption was based on the fact that hyperglycaemia in diabetic patients is typically associated with excessive angiogenesis in different organs, which, for example, causes diabetic retinopathy and nephropathy (Aouiss *et al.*, 2019; Zent and Pozzi, 2007). In line with this finding, several *in vitro* studies have reported that highglucose-treated endothelial cells exhibit an increased proliferating, migrating and tube-forming activity due to the upregulation of angiogenic signalling pathways (Betts-Obregon *et al.*, 2016; Fernando *et al.*, 2018; Qiu *et al.*, 2018; Shi *et al.*, 2019).

To test the study hypothesis, ad-MVF isolated from epididymal fat pads of donor mice were exposed *in vitro* for 24 h to high glucose and their protein expression, morphology, viability and proliferation were analysed in comparison to vehicle-exposed controls. Moreover, collagen-glycosaminoglycan scaffolds seeded with high-glucose- and vehicleexposed ad-MVFs were implanted into dorsal skinfold chambers of recipient mice to study their *in vivo* vascularisation and incorporation.

Materials and Methods

Ethical statement

The study was approved by the local governmental animal protection committee (Landesamt für Verbraucherschutz, Abteilung C Lebensmittel- und Veterinärwesen, Saarbrücken, Germany; permission number: 29/2014). All experiments were conducted in accordance with the Directive 2010/63/EU and the NIH Guidelines for the Care and Use of Laboratory Animals (NIH Publication #85-23 Rev. 1985).

Animals

For the isolation of ad-MVF, male C57BL/6 wild-type mice and C57BL/6-TgN(ACTB-EGFP)1Osb/J mice (age: 6-12 months; body weight: > 30 g; Institute for Clinical and Experimental Surgery, Saarland University, Homburg/Saar, Germany) were used as fat donors. The latter ubiquitously express green fluorescent protein (GFP) (Okabe *et al.*, 1997). Dorsal skinfold chambers were implanted into C57BL/6 wild-type mice (age: 3-5 months; body weight: 22-27 g). Animals were housed in the animal facility of the Institute for Clinical and Experimental Surgery (Saarland University, Homburg/Saar, Germany) with access to tap water and standard pellet food *ad libitum* (Altromin, Lage, Germany).

Isolation and cultivation of ad-MVF

Ad-MVF were isolated from the epididymal fat pads of donor mice (Fig. 1a-c), as described previously in detail (Frueh et al., 2017b). In brief, the donor animals were anaesthetised by intraperitoneal injection of ketamine (100 mg/kg body weight; Ursotamin, Serumwerk Bernburg AG, Bernburg, Germany) and xylazine (12 mg/kg body weight; Rompun, Bayer, Leverkusen, Germany), laparotomised and sacrificed by incision of the abdominal aorta. The epididymal fat pads were excised, mechanically minced and digested in collagenase NB4G (0.5 U/mL; Serva, Heidelberg, Germany) for 9 min while being stirred at 37 °C under humidified atmospheric conditions. Subsequently, the enzyme was neutralised with phosphate-buffered saline (PBS) containing 20 % foetal calf serum (FCS) and the suspension was filtered through a 500 µm mesh (pluriSelect Life Science, Leipzig, Germany) to remove non-digested fat clots. Moreover, fat supernatants were carefully removed. The remaining ad-MVF were finally enriched up to a pellet size by centrifugation for 5 min at 120 ×g.

The isolated ad-MVF were cultivated for 24 h under humidified conditions in 1 % agarose-coated 24-well plates containing 4 °C University of Wisconsin (UW) solution (Belzer UW Cold Storage Solution, Bridge to Life Ltd., Columbia, SC, USA). These culture conditions have previously been proven to be suitable for the xeno-free cultivation of ad-MVF, as it would be necessary in future clinical practice (Laschke *et al.*, 2019b). The UW solution was supplemented with 30 mM glucose (high glucose; Carl Roth, Karlsruhe, Germany) or vehicle (control; PBS). At the end of the 24 h cultivation period, the ad-MVF were washed in PBS prior to further analyses.

Protein expression of ad-MVF

The expression of 53 pro- and anti-angiogenic proteins was analysed in vehicle- and high-glucose-exposed ad-MVF by means of a proteome profiler mouse angiogenesis array kit (R&D Systems, Wiesbaden, Germany), as described previously in detail (Laschke *et al.*, 2018).

Scaffold preparation and seeding

Vehicle- and high-glucose-exposed ad-MVF were seeded on to clinically available collagenglycosaminoglycan scaffolds (Integra[®]; Integra GmbH, Ratingen, Germany) having a diameter of 3 mm (Fig. 1c). A detailed description of the scaffold preparation and seeding procedure is given in Laschke *et al.* (2019b).






Fig. 1. Isolation of ad-MVF and experimental model. (a) Epididymal fat pad of a C57BL/6 donor mouse. Scale bar: 3.5 mm. (**b**) Brightfield microscopy of an ad-MVF (arrow) directly after enzymatic isolation from the epididymal fat pad. Scale bar: 35 µm. (c) Schematic overview of the ad-MVF isolation and preparation procedure. Ad-MVF were isolated by enzymatic digestion of the epididymal fat pads of donor mice. After the removal of fat supernatants, ad-MVF were enriched up to a pellet size and subsequently cultivated for 24 h in 4 °C UW solution containing high glucose or vehicle. Thereafter, the ad-MVF were seeded on to collagenglycosaminoglycan scaffolds for further in vitro and in vivo analyses. (d) C57BL/6 mouse with a dorsal skinfold chamber. Scale bar: 12.5 mm. (e) Stereomicroscopy of the observation window of a dorsal skinfold chamber after the implantation of an ad-MVF-seeded collagen-glycosaminoglycan scaffold (borders marked by broken line). Scale bar: 1.5 mm.

Morphology of ad-MVF

The morphology of vehicle- and high-glucose-exposed ad-MVF seeded on to collagen-glycosaminoglycan scaffolds was analysed by means of a FEI XL-30 ESEM FEG scanning electron microscopy device (FEI, Hillsboro, OR, USA). A detailed description of the sample preparation is given in Laschke *et al.* (2018).

Dorsal skinfold chamber model and intravital fluorescence microscopy

Vehicle- and high-glucose-exposed ad-MVF from GFP⁺ donor mice were seeded on to collagenglycosaminoglycan scaffolds, which were implanted into dorsal skinfold chambers of GFP⁻ recipient mice (Fig. 1d,e) and analysed by means of intravital fluorescence microscopy, as described previously in detail (Laschke *et al.*, 2019a). For contrast enhancement by intravascular staining of plasma, 100 μ L 5 % FITC-labelled dextran 150,000 (Sigma-Aldrich) were injected before each microscopy analysis into the retrobulbary plexus of the anaesthetised mice. The microscopy images were analysed with the computer-assisted off-line analysis system CapImage (Zeintl, Heidelberg, Germany). The vascularisation of the implants was assessed in 8 regions of interest (ROIs). Perfused ROIs (in percentage of all ROIs) were defined as areas containing either newly developed red blood cell (RBC)-perfused microvessels or reperfused GFP⁺ ad-MVF. In addition, the functional microvessel density, *i.e.* the length of all RBC-perfused microvessels per ROI given in cm/cm², as well as the diameter (D; given in μ m) and the centreline RBC velocity (v; given in μ m/s) of 30 randomly selected perfused microvessels within the implants were measured. The wall shear rate (y; given in s⁻¹) of these vessels was then calculated with the formula: y = 8 × v/D.

Experimental protocol

For *in vitro* analyses, ad-MVF were isolated from epididymal fat pads of 32 GFP⁻ donor mice. Isolated ad-MVF were divided into two equal parts and cultivated for 24 h in 4 °C UW solution, which was supplemented with vehicle or high



Table 1. Expression of angiogenesis-related proteins (percentage of vehicle) in ad-MVF as assessed by a proteome profiler mouse angiogenesis array. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with vehicle or high glucose.

Protein	Expression (percentage of vehicle)
	giogenic
Endoglin/CD105	203.2
IL-1β	190.0
MCP-1/CCL2/JE	184.5
HGF	152.4
KC/CXCL1/CINC-1/GROα	148.9
EGF	128.0
Osteopontin/OPN	113.9
FGF basic/FGF-2	113.2
SDF-1/CXCL 12	110.7
Leptin/OB	107.3
GM-CSF	102.0
Angiogenin/ANG	101.7
FGF acid/FGF-1/ECGF/HBGF-1	99.8
Amphiregulin/AR	99.7
Angiopoietin-1/Ang-1	95.3
Coagulator factor III/Tissue factor/TF	95.3
Endothelin-1/ET-1	94.4
DLL4	92.5
MMP-9	90.9
CXCL 16	90.7
NOV/CCN3/IGFBP-9	90.6
KGF/FGF-7	90.1
IL-1	89.9
IGFBP-2	89.7
IGFBP-1	87.4
VEGF B/VRF	87.2
Cyr61/CCN1, IGFBP-10	83.7
HB-EGF	83.6
VEGF/VPF	82.3
PDGF-AA	79.8
Fractalkine/CX3CL 1	79.3
Proliferin	67.2
IL-10/CSIF	67.0
MIP-1α	65.8
PD-ECGF	64.7
MMP-3	64.7
PIGF-2	62.2
IGFBP-3	60.1
MMP-8	38.7
	giogenic
Endostatin/Collagen VIII	148.8
Serpin E1/PAI-1	111.6
ADAMTS1/METH1	106.9
DPP IV/CD26	104.1
PDGF-AB/BB	103.0
Platelet factor 4/CXCL4/PF4	102.6
Thrombospondin-2/TSP-2	83.8
Serpin F1/PEDF	79.5
Pentraxin-3/PTX3/TSG-14	74.3
Prolactin/PRL	66.5
TIMP-4	63.4
IP-10/CXCL 10	63.3
Angiopoietin-3/Ang-3	60.8
TIMP-1	42.6



glucose. Immediately after cultivation, the protein expression of the ad-MVF was analysed by means of a proteome profiler mouse angiogenesis array kit (n = 2 per group). Additional ad-MVF were seeded on to collagen-glycosaminoglycan scaffolds to study their morphology by means of scanning electron microscopy (n = 2 per group) and their viability and proliferation by means of immunohistochemistry (n = 4 per group).

For *in vivo* analyses, ad-MVF were isolated from the epididymal fat pads of 20 GFP⁺ donor mice and cultivated as described above. Subsequently, they were seeded on to collagen-glycosaminoglycan scaffolds, which were implanted into the dorsal skinfold chambers of 18 GFP⁻ recipient mice (vehicle: n = 9; high glucose: n = 9). The scaffolds were analysed directly after implantation (day 0) and on days 3, 6, 10 and 14 by means of intravital fluorescence microscopy. Thereafter, animals were sacrificed with an overdose of anaesthetics and the implants with the surrounding tissue were excised for further histological and immunohistochemical analyses.

Histology and immunohistochemistry

Formalin-fixed specimens of ad-MVF-seeded nonimplanted and implanted scaffolds were embedded in paraffin-wax and cut into 3 µm-thick sections. Sections were stained with haematoxylin and eosin (HE), sirius red and antibodies against the apoptosis marker cleaved caspase (Casp)-3, the proliferation marker Ki67, the endothelial marker CD31 and the fluorescence marker GFP, as described previously in detail (Laschke *et al.*, 2019a). Sections were analysed using a BX60 microscope (Olympus, Hamburg, Germany).

Collagen content of implanted ad-MVF-seeded scaffolds, as assessed by means of the reddish appearance of mature sirius-red-stained collagen type I fibres under polarised-light microscopy in relation to normal skin, was measured in 4 ROIs of each sample using the imaging software cellSens Dimension 1.11 (Olympus) (Frueh et al., 2017a). Additional quantitative analyses included the determination of the fractions of Casp-3⁺ and Ki67⁺ cells (given in percentage) in randomly selected ad-MVF, including at least 100 endothelial and perivascular cells per sample. Moreover, the density of all CD31⁺ microvessels (given in mm⁻²) and the fraction of CD31⁺/GFP⁺ microvessels of all CD31⁺ microvessels (given in percentage) were assessed in the centre and border zones of ad-MVF-seeded implants.

Statistical analysis

Data were tested for normal distribution and equal variance. In case of parametric distribution of the data, differences between the groups were analysed by unpaired Student's *t*-test. In case of non-




Fig. 2. Morphology of ad-MVF. (a-d) Scanning electron microscopy of ad-MVF directly after their seeding on to collagen-glycosaminoglycan matrices. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with (a,b) vehicle or (c,d) high glucose. Arrows = pericytes; arrowheads = nanopores. (b,d) Higher magnification (scale bar: 1.4 μ m) of inserts in a and c (scale bar: 11 μ m).



parametric distribution of the data, differences were assessed by Mann-Whitney rank sum test (SigmaPlot 11.0; Jandel Corporation, San Rafael, CA, USA). All values are given as mean \pm standard error of the mean (SEM). Statistical significance was accepted for a value of p < 0.05.

Results

ad-MVF protein expression

In a first set of experiments, a proteome profiler mouse angiogenesis array was performed to analyse the expression of pro- and anti-angiogenic factors in cultivated ad-MVF. This array revealed a difference in protein expression pattern between vehicle- and highglucose-treated ad-MVF (Table 1). In comparison to controls, the most increased protein levels were detected in high-glucose-exposed ad-MVF for the pro-angiogenic factors endoglin, interleukin (IL)- 1β and monocyte chemoattractant protein (MCP)-1. In contrast, the pro-angiogenic factor matrix metalloproteinase (MMP)-8 and its counterpart tissue inhibitor of matrix metalloproteinase (TIMP)-1 were the most downregulated proteins (Table 1).

Morphology of ad-MVF

Ad-MVF were seeded on to collagenglycosaminoglycan scaffolds directly after the 24 h-cultivation period and analysed by means




Fig. 3. Viability and proliferation of ad-MVF. (**a**-**d**) Fluorescence microscopy of ad-MVF directly after their seeding on to collagen-glycosaminoglycan matrices. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with (**a**,**c**) vehicle or (**b**,**d**) high glucose. (**a**-**d**) Staining was performed with Hoechst 33342 (blue) for the detection of cell nuclei and an antibody against CD31 (green) for the identification of endothelial cells in combination with an antibody against (**a**,**b**) Casp-3 (red) for the labelling of apoptotic cells or (**c**,**d**) against Ki67 (red) for the labelling of proliferating cells. Arrows = marker-positive endothelial cells; arrowheads = marker-positive perivascular cells. Scale bars: 10 µm. Percentage of (**e**) Casp-3⁺ cells and (**f**) Ki67⁺ cells within ad-MVF, which were cultivated for 24 h in 4 °C UW solution supplemented with vehicle (white bars, *n* = 4) or high glucose (black bars, *n* = 4). Mean ± SEM; * *p* < 0.05 *vs.* vehicle.



of scanning electron microscopy to assess their morphology (Fig. 2**a**-**d**). Both high-glucose- and vehicle-exposed ad-MVF exhibited a comparable vessel morphology, with attached stabilising pericytes (Fig. 2**a**,**c**). However, higher magnifications revealed multiple nanopores in high-glucose-exposed ad-MVF, which could not be observed in vehicletreated controls, indicating a beginning disintegration of their vessel walls (Fig. 2**b**,**d**).

Viability and proliferation of ad-MVF

Immunohistochemical analyses showed a comparable fraction of Casp-3⁺ apoptotic endothelial and perivascular cells in vehicle- and high-glucoseexposed ad-MVF (Fig. 3**a**,**b**,**e**). In contrast, highglucose-exposed ad-MVF exhibited a significantly higher number of Ki67⁺ proliferating endothelial and perivascular cells when compared to controls (Fig. 3**c**,**d**,**f**).

In vivo vascularisation capacity of ad-MVF

To assess their *in vivo* vascularisation capacity, GFP⁺ vehicle- and high-glucose-exposed ad-MVF

were seeded on to collagen-glycosaminoglycan scaffolds, which were implanted into the dorsal skinfold chambers of GFP- wild-type recipient mice. Repetitive intravital fluorescent microscopy analyses of the implants revealed that ad-MVF of both groups were able to rapidly reassemble into microvascular networks (Fig. 4a-j). These networks also developed interconnections to the surrounding host microvasculature. Accordingly, there were no significant differences in the fraction of perfused ROIs between the two groups throughout the 14 d-observation period (Fig. 4k). However, more detailed analyses of the newly developing networks showed a significantly higher functional microvessel density in scaffolds seeded with high-glucoseexposed ad-MVF between day 6 and 14 when compared to controls (Fig. 41). In addition, individual microvessels within these scaffolds presented with a significantly smaller diameter and higher centreline RBC velocity at later observation time points (Fig. 5a-d). Accordingly, the calculated wall shear rate of these vessels was also significantly higher when compared to controls (Fig. 5e). These findings




Fig. 4. *In vivo* vascularisation capacity of ad-MVF. (a-j) Intravital fluorescence microscopy (blue-light epiillumination with contrast enhancement by 5 % FITC-labelled dextran 150,000 injected intravenous) of ad-MVF-seeded collagen-glycosaminoglycan scaffolds on day 0, 3, 6, 10 and 14 after implantation into the dorsal skinfold chamber of C57BL/6 mice. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with (a-e) vehicle or (f-j) high glucose. Arrows = GFP⁺ ad-MVF. Scale bars: 85 µm. (k) Percentage of perfused ROIs and (l) functional microvessel density (cm/cm²) of ad-MVF-seeded collagen-glycosaminoglycan scaffolds directly (0 d) as well as 3, 6, 10 and 14 d after implantation into dorsal skinfold chambers, as assessed by intravital fluorescence microscopy. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with vehicle (white circles, *n* = 9) or high glucose (black circles, *n* = 9). Mean ± SEM; * *p* < 0.05 *vs.* vehicle.






Fig. 5. Vascular maturation and remodelling of ad-MVF. (a,b) Intravital fluorescence microscopy (bluelight epi-illumination with contrast enhancement by 5 % FITC-labelled dextran 150,000 injected intravenous) of individual microvessels within ad-MVF-seeded collagen-glycosaminoglycan scaffolds on day 14 after implantation into the dorsal skinfold chamber of C57BL/6 mice. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with (a) vehicle or (b) high glucose. Scale bars: 20 μm. (c) Diameter (µm), (d) centreline RBC velocity $(\mu m/s)$ and (e) wall shear rate (s^{-1}) of individual microvessels within ad-MVF-seeded collagenglycosaminoglycan scaffolds 3, 6, 10 and 14 d after implantation into dorsal skinfold chambers, as assessed by intravital fluorescence microscopy. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with vehicle (white circles, n = 9) or high glucose (black circles, n = 9). Mean ± SEM; *p < 0.05 vs. vehicle.

indicated an improved vascularisation as well as vascular maturation and remodelling of the scaffolds with the high-glucose-exposed ad-MVF.

At the end of the *in vivo* experiments, ad-MVFseeded scaffolds were additionally analysed by means of histology and immunohistochemistry. HE-stained sections showed a denser granulation tissue within the pores and the surrounding host tissue of implants seeded with high-glucose-exposed ad-MVF (Fig. 6a,b). These scaffolds also exhibited a significantly higher microvessel density in their border zones when compared to controls (Fig. 6c, f, i). In contrast, the microvessel density in the centre of the implants was comparable in both groups (Fig. 6i). Moreover, they presented with a comparably high fraction of > 80 % GFP⁺ microvessels in their border and centre zones (Fig. 6d,e,g,h,j). Finally, the analysis of sirius-red-stained sections revealed a tendency towards a higher total collagen ratio in scaffolds seeded with high-glucose-exposed ad-MVF, indicating an improved tissue incorporation when compared to controls (Fig. 6k-n).

Discussion

The present study demonstrated that exposure of cultivated ad-MVF to high glucose concentrations promoted their proliferation and in vivo network formation. Hence, this novel approach may improve the outcome of future therapeutic interventions using ad-MVF as vascularisation units. The shortterm cultivation of ad-MVF may be particularly recommended in clinical cases in which freshly isolated ad-MVF cannot be directly retransferred into patients due to prolonged or multi-step surgical procedures. For this purpose, ad-MVF should be cultivated at 4 °C in UW solution to prevent their agglomeration and to ensure xeno-free culture conditions according to good manufacturing practices (Laschke et al., 2019b). Those novel results indicated that these conditions can be further optimised by adding 30 mM glucose to the UW solution, which is, in contrast to the use of recombinant growth factors, a cost-effective and, from a regulatory point of view, harmless approach to effectively increase the angiogenic activity of ad-MVF.

The pro-angiogenic effect of high glucose is not a novel finding but well known from studies focusing on the mechanisms underlying diabetes-induced aberrant angiogenesis (Betts-Obregon *et al.*, 2016; Fernando *et al.*, 2018; Qiu *et al.*, 2018; Shi *et al.*, 2019). Such studies are often performed with endothelial cell monocultures that are exposed to different glucose concentrations. In contrast, in the present study, ad-MVF were used with an intact vessel morphology and physiological cellular composition, including microvessel-attached pericytes. Hence, these fully functional vessel segments may provide more realistic conditions to study the effects of high






Fig. 6. Final vascularisation and incorporation of ad-MVF-seeded scaffolds. (a,b) HE-stained sections of ad-MVF-seeded collagen-glycosaminoglycan scaffolds (borders marked by broken line) on day 14 after implantation into the dorsal skinfold chamber of C57BL/6 mice. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with (a) vehicle or (b) high glucose. Scale bars: 350 µm. (c-h) Immunohistochemically stained microvessels in the border of ad-MVF-seeded collagen-glycosaminoglycan scaffolds on day 14 after implantation into the dorsal skinfold chambers of C57BL/6 mice. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with (c-e) vehicle or (f-h) high glucose. (c-h) Staining was performed with Hoechst 33342 to identify cell nuclei (blue), (c,f) an antibody against CD31 for the detection of endothelial cells (red) and (d,g) an antibody against GFP (green). (e,h) Merge of c,d and f,g. Arrows = CD31⁺/GFP⁺ microvessels; arrowheads = CD31⁺/GFP⁻ microvessels. Scale bars: 25 μ m. (i) Microvessel density (mm⁻²) and (j) GFP⁺ microvessels percentage in the centre and border zones of ad-MVF-seeded collagen-glycosaminoglycan scaffolds 14 d after implantation into the dorsal skinfold chamber, as assessed by immunohistochemical analysis. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with vehicle (white bars, n = 9) or high glucose (black bars, n = 9). Mean \pm SEM; * p < 0.05 vs. vehicle. Sirius-red-stained sections of (k) normal skin as well as (l,m) ad-MVF-seeded collagen-glycosaminoglycan scaffolds on day 14 after implantation into the dorsal skinfold chamber of C57BL/6 mice. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with (1) vehicle or (m) high glucose. Scale bars: 30 μ m. (n) Total collagen ratio in ad-MVFseeded collagen-glycosaminoglycan scaffolds 14 d after implantation into the dorsal skinfold chamber, as assessed by histological analysis. ad-MVF were cultivated for 24 h in 4 °C UW solution supplemented with vehicle (white bar, n = 9) or high glucose (black bar, n = 9). Mean \pm SEM.



glucose on microvessels and, thus, may also be recommended as explants for future *in vitro* studies in diabetes research. In line with this view, not only was the stimulating effect of glucose on endothelial cell proliferation (Fernando et al., 2018; Qiu et al., 2018) confirmed, but also larger numbers of Ki67⁺ proliferating perivascular cells were detected in high-glucose-exposed ad-MVF when compared to vehicle-exposed controls. This indicated that vessel-wall-stabilising cells crucially contribute to diabetes-related microvasculopathy. Moreover, scanning electron microscopy analyses revealed that high-glucose-exposed ad-MVF exhibited multiple nanopores. On the one hand, these nanopores may result from glucose-induced cellular damage and beginning necrosis. On the other hand, they may be interpreted as an early sign of angiogenesis, which is typically associated with an increased vascular permeability, degradation of the basal lamina and disintegration of the vessel wall (Díaz-Flores *et al.*, 2017). When getting larger, these nanopores may also represent the morphological correlate to the haemorrhages that are clinically observed in diabetic retinopathy (Murugesan et al., 2015). Diabetes-induced microvascular abnormalities additionally include microaneurysms, exudates and microthromboses (Murugesan et al., 2015), indicating an impaired vessel functionality. Hence, it is reasonable to assume that a longer exposure to supraphysiological glucose levels, as they occur in diabetic patients, would rather reduce the regenerative potential of ad-MVF. However, this issue needs further clarification.

A major prerequisite for the reassembly of ad-MVF into new microvascular networks is their growth towards each other by the process of sprouting angiogenesis (Nunes et al., 2010). This process is initiated and driven by the complex interplay of multiple pro- and anti-angiogenic factors (Weis and Cheresh, 2011). To study the effect of high glucose on the expression of these factors, a proteome profiler mouse angiogenesis array was performed. Of interest, an altered protein expression pattern was found in high-glucose-exposed ad-MVF, with endoglin, IL-1 β and MCP-1 as the most upregulated factors when compared to vehicleexposed controls. Endoglin is a glycoprotein, which is typically upregulated in angiogenic endothelial cells, where it promotes proliferation and migration via transforming growth factor (TGF)-β/activin receptorlike kinase (ALK)1/Smad1/5/8 signalling (Kasprzak and Adamek, 2018). IL-1 β and MCP-1 are primarily known as pro-inflammatory cytokines, which recruit different immune cell types to sites of inflammation (Bianconi et al., 2018; Fenini et al., 2017). However, several studies have shown that they also exert proangiogenic effects, indicating a close link between inflammation and angiogenesis (Hayashi et al., 2015; Mohr et al., 2017; Sun et al., 2016). Of note, this link is a typical feature of diabetes-related angiogenic pathologies too (Capitão and Soares, 2016). In addition, a strong down-regulation of pro-angiogenic factors, such as MMP-8, was detected that did not, however, shift the analysed ad-MVF towards an antiangiogenic phenotype. This may be explained by the fact that anti-angiogenic factors, such as TIMP-1, the counterpart of MMP-8, were also down-regulated in high-glucose-exposed ad-MVF.

To assess their in vivo vascularisation capacity, vehicle- and high-glucose-exposed ad-MVF from GFP⁺ donor mice were analysed in dorsal skinfold chambers of GFP⁻ recipient animals. By means of this GFP⁺/GFP⁻ cross-over design, it was demonstrated that in both groups most of the GFP⁺ ad-MVF survived and mainly contributed to the final vascularisation of the seeded scaffolds at day 14 after implantation. However, this vascularisation was markedly improved in the group of high-glucose-treated ad-MVF, as indicated by a significantly higher functional microvessel density when compared to controls. This finding was in line with the pro-angiogenic effects of high glucose observed in the *in vitro* analyses. Besides these effects, other mechanisms may have further contributed to this positive outcome. In fact, Yoon et al. (2014) reported that high glucose conditions induce Jagged1 and suppress Notch1 expression in endothelial cells. These conditions promote the specification of endothelial cells to the tip cell phenotype, which is highly motile and guides endothelial sprouts towards growth factor stimuli (Chen et al., 2019). Accordingly, Yoon et al. (2014) additionally detected an increased angiogenic sprouting and branching of glucose-exposed endothelial cell/smooth muscle cell spheroids, resulting in a higher density of newly developing microvascular networks. Furthermore, high shear forces, as assessed in the present study in individual microvessels of the high glucose group, stimulate vascular sprouting (Galie *et al.*, 2014).

Conclusion

Exposure of cultivated ad-MVF to high glucose concentrations resulted to be a promising approach to improve their in vivo vascularisation capacity. A rapid and sufficient vascularisation is of pivotal importance for the incorporation of biomaterials into the surrounding host tissue (Reichel et al., 2015). In the present study, this was reflected by a denser granulation tissue and a higher collagen content within the scaffolds seeded with high-glucoseexposed ad-MVF when compared to controls. In addition, survival and long-term function of implanted tissue constructs was crucially determined by an adequate blood supply (Laschke et al., 2006). Hence, high-glucose-exposed ad-MVF may serve as versatile vascularisation units to use in a wide range of future applications in the fields of implant research, tissue engineering and regenerative medicine.



Acknowledgements

We are grateful for the excellent technical assistance of Janine Becker, Caroline Bickelmann and Julia Parakenings (Institute for Clinical and Experimental Surgery, Saarland University, Homburg/Saar, Germany). This study was funded by a grant of the Deutsche Forschungsgemeinschaft (DFG - German Research Foundation) - LA 2682/7-1.

References

Aouiss A, Anka Idrissi D, Kabine M, Zaid Y (2019) Update of inflammatory proliferative retinopathy: ischemia, hypoxia and angiogenesis. Curr Res Transl Med **67**: 62-71.

Betts-Obregon BS, Vellanki S, Buikema J, Tsin AT, Wright K (2016) Effect of glucose on retinal endothelial cell viability and VEGF secretion. HSOA J Cell Biol Cell Metabol **3**: 008. DOI: 10.24966/CBCM-1943/100008.

Bianconi V, Sahebkar A, Atkin SL, Pirro M (2018) The regulation and importance of monocyte chemoattractant protein-1. Curr Opin Hematol **25**: 44-51.

Capitão M, Soares R (2016) Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem **117**: 2443-2453.

Chen W, Xia P, Wang H, Tu J, Liang X, Zhang X, Li L (2019) The endothelial tip-stalk cell selection and shuffling during angiogenesis. J Cell Commun Signal **13**: 291-301.

Díaz-Flores L, Gutiérrez R, García-Suárez MP, Sáez FJ, Gutiérrez E, Valladares F, Carrasco JL, Díaz-Flores L Jr, Madrid JF (2017) Morphofunctional basis of the different types of angiogenesis and formation of postnatal angiogenesis-related secondary structures. Histol Histopathol **32**: 1239-1279.

Fenini G, Contassot E, French LE (2017) Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases. Front Pharmacol 8: 278. DOI: 10.3389/fphar.2017.00278.

Fernando KHN, Yang HW, Jiang Y, Jeon YJ, Ryu B (2018) Diphlorethohydroxycarmalol isolated from Ishige okamurae represses high glucose-induced angiogenesis *in vitro* and *in vivo*. Mar Drugs **16**. pii: E375. DOI: 10.3390/md16100375.

Frueh FS, Später T, Lindenblatt N, Calcagni M, Giovanoli P, Scheuer C, Menger MD, Laschke MW (2017a) Adipose tissue-derived microvascular fragments improve vascularization, lymphangiogenesis, and integration of dermal skin substitutes. J Invest Dermatol **137**: 217-227.

Frueh FS, Später T, Scheuer C, Menger MD, Laschke MW (2017b) Isolation of murine adipose tissuederived microvascular fragments as vascularization units for tissue engineering. J Vis Exp **122**. DOI: 10.3791/55721. Galie PA, Nguyen DH, Choi CK, Cohen DM, Janmey PA, Chen CS (2014) Fluid shear stress threshold regulates angiogenic sprouting. Proc Natl Acad Sci U S A **111**: 7968-7973.

Hayashi Y, Murakami M, Kawamura R, Ishizaka R, Fukuta O, Nakashima M (2015) CXCL14 and MCP1 are potent trophic factors associated with cell migration and angiogenesis leading to higher regenerative potential of dental pulp side population cells. Stem Cell Res Ther **6**: 111. DOI: 10.1186/s13287-015-0088-z.

Karschnia P, Scheuer C, Heß A, Später T, Menger MD, Laschke MW (2018) Erythropoietin promotes network formation of transplanted adipose tissuederived microvascular fragments. Eur Cell Mater **35**: 268-280.

Kasprzak A, Adamek A (2018) Role of endoglin (CD105) in the progression of hepatocellular carcinoma and anti-angiogenic therapy. Int J Mol Sci **19**. pii: E3887. DOI: 10.3390/ijms19123887.

Laschke MW, Harder Ý, Amon M, Martin I, Farhadi J, Ring A, Torio-Padron N, Schramm R, Rücker M, Junker D, Häufel JM, Carvalho C, Heberer M, Germann G, Vollmar B, Menger MD (2006) Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. Tissue Eng **12**: 2093-2104.

Laschke MW, Kleer S, Scheuer C, Schuler S, Garcia P, Eglin D, Alini M, Menger MD (2012) Vascularisation of porous scaffolds is improved by incorporation of adipose tissue-derived microvascular fragments. Eur Cell Mater **24**: 266-277.

Laschke MW, Menger MD (2015) Adipose tissue-derived microvascular fragments: natural vascularization units for regenerative medicine. Trends Biotechnol **33**: 442-448.

Laschke MW, Karschnia P, Scheuer C, Heß A, Metzger W, Menger MD (2018) Effects of cryopreservation on adipose tissue-derived microvascular fragments. J Tissue Eng Regen Med **12**: 1020-1030.

Laschke MW, Heß A, Scheuer C, Karschnia P, Menger MD (2019a) Subnormothermic short-term cultivation improves the vascularization capacity of adipose tissue-derived microvascular fragments. J Tissue Eng Regen Med **13**: 131-142.

Laschke MW, Heß A, Scheuer C, Karschnia P, Kontaxi E, Menger MD (2019b) University of Wisconsin solution for the xeno-free storage of adipose tissue-derived microvascular fragments. Regen Med **14**: 681-691.

Madri JA, Williams SK (1983) Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol **97**: 153-165.

McDaniel JS, Pilia M, Ward CL, Pollot BE, Rathbone CR (2014) Characterization and multilineage potential of cells derived from isolated microvascular fragments. J Surg Res **192**: 214-222.

Mohr T, Haudek-Prinz V, Slany A, Grillari J, Micksche M, Gerner C (2017) Proteome profiling



in IL-1 β and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis. PLoS One **12**: e0179065. DOI: 10.1371/journal.pone.0179065.

Murugesan N, Üstunkaya T, Feener EP (2015) Thrombosis and hemorrhage in diabetic retinopathy: a perspective from an inflammatory standpoint. Semin Thromb Hemost **41**: 659-664.

Nunes SS, Greer KA, Stiening CM, Chen HY, Kidd KR, Schwartz MA, Sullivan CJ, Rekapally H, Hoying JB (2010) Implanted microvessels progress through distinct neovascularization phenotypes. Microvasc Res **79**: 10-20.

Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y (1997) 'Green mice' as a source of ubiquitous green cells. FEBS Lett **407**: 313-319.

Qiu F, Tong H, Wang Y, Tao J, Wang H, Chen L (2018) Recombinant human maspin inhibits high glucose-induced oxidative stress and angiogenesis of human retinal microvascular endothelial cells *via* PI3K/AKT pathway. Mol Cell Biochem **446**: 127-136.

Reichel CA, Hessenauer ME, Pflieger K, Rehberg M, Kanse SM, Zahler S, Krombach F, Berghaus A, Strieth S (2015) Components of the plasminogen activation system promote engraftment of porous polyethylene biomaterial *via* common and distinct effects. PLoS One **10**: e0116883. DOI: 10.1371/journal. pone.0116883.

Sato N, Nariuchi H, Tsuruoka N, Nishihara T, Beitz JG, Calabresi P, Frackelton AR Jr (1990) Actions of TNF and IFN-gamma on angiogenesis *in vitro*. J Invest Dermatol **95**: 85S-89S.

Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Raymond A, Frackelton AR Jr (1993) Platelet-derived growth factor indirectly stimulates angiogenesis *in vitro*. Am J Pathol **142**: 1119-1130.

Shepherd BR, Hoying JB, Williams SK (2007) Microvascular transplantation after acute myocardial infarction. Tissue Eng **13**: 2871-2879.

Shi Y, Chen C, Xu Y, Liu Y, Zhang H, Liu Y (2019) LncRNA FENDRR promotes high-glucose-induced proliferation and angiogenesis of human retinal endothelial cells. Biosci Biotechnol Biochem **83**: 869-875.

Später T, Frueh FS, Nickels RM, Menger MD, Laschke MW (2018) Prevascularization of collagenglycosaminoglycan scaffolds: stromal vascular fraction *versus* adipose tissue-derived microvascular fragments. J Biol Eng **12**: 24. DOI: 10.1186/s13036-018-0118-3.

Sun J, Chen J, Cao J, Li T, Zhuang S, Jiang X (2016) IL-1 β -stimulated β -catenin up-regulation promotes angiogenesis in human lung-derived mesenchymal stromal cells through a NF- κ B-dependent microRNA-433 induction. Oncotarget 7: 59429-59440.

Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med **17**: 1359-1370.

Williams SK, Devenny JJ, Bitensky MW (1981) Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci U S A **78**: 2393-2397.

Yoon CH, Choi YE, Koh SJ, Choi JI, Park YB, Kim HS (2014) High glucose-induced jagged 1 in endothelial cells disturbs notch signaling for angiogenesis: a novel mechanism of diabetic vasculopathy. J Mol Cell Cardiol **69**: 52-66.

Zent R, Pozzi A (2007) Angiogenesis in diabetic nephropathy. Semin Nephrol **27**: 161-171.

Discussion with Reviewers

Daniel Schmauss: How did you choose the glucose concentration used? Could higher glucose concentrations have an even more pronounced effect? **Authors**: The glucose concentration was chosen based on previous *in vitro* studies focusing on the angiogenic effects of glucose on endothelial cells (Betts-Obregon *et al.*, 2016; Fernando *et al.*, 2018; Qiu *et al.*, 2018). In these studies, a concentration of 30 mM glucose is typically used to mimic hyperglycaemic conditions, as they occur in diabetic patients.

Daniel Schmauss: Do you think the nanopores in the vessel wall, described in the high-glucose group, might have a negative impact on the performance of the used ad-MVF if they would get larger? Or is this improbable given the short-term exposure to high glucose concentrations?

Authors: The observed nanopores may be interpreted in different ways. On the one hand, they may result from glucose-induced cellular damage and beginning necrosis. In this case, they would probably have a negative impact on the *in vivo* performance of the ad-MVF. On the other hand, they may be interpreted as an early sign of angiogenesis, which is typically associated with an increased vascular permeability, degradation of the basal lamina and disintegration of the vessel wall (Díaz-Flores *et al.*, 2017). If this holds true, the nanopores would have a positive impact when getting larger during glucose exposure, resulting in an accelerated *in vivo* reassembly of individual ad-MVF into new microvascular networks.

Heiko Sorg: Have you tested systemic glucose administration?

Authors: No, in the present study, the systemic treatment of mice with high glucose concentrations was deliberately omitted. In fact, the aim was to test a new approach for improving the *in vivo* vascularisation capacity of ad-MVF without affecting the physiological health status of the recipients. In clinical practice, such an approach would be much more attractive, because potential side effects of a systemic treatment could be avoided. Nonetheless, we feel that the reviewer addresses the interesting question of how ad-MVF would perform when applied in diabetic patients. Since the prevalence of diabetes is continuously increasing, being particularly



high in older patients, who may also represent a main target group for future tissue engineering therapies, this relevant issue should be clarified in further experimental studies.

Heiko Sorg: From a clinical point of view, might liposuction be also sufficient to gain significant amounts of adMVF?

Authors: The isolation of ad-MVF from human liposuctioned fat is the desirable method for the future application of this concept in clinical practice. Currently, protocols are being developed to promote exactly this approach and, based on preliminary results, it seems possible to gain sufficient amounts of ad-MVF from this fat source.

Heiko Sorg: What would you presume would happen if exposing adMVF for more than 24 h to high glucose concentrations (< 72 h)? Might the shown effects be decreased?

Authors: We do not recommend exposing ad-MVF *in vitro* for more than 24 h to high glucose concentrations. In fact, ad-MVF lose their physiological vessel morphology when cultivated longer. Accordingly, they also exhibit an impaired *in vivo* vascularisation capacity (Laschke *et al.*, 2015, additional reference). For these reasons, it is possible that the shown effects would indeed be decreased.

Heiko Sorg: The increase in collagen might also lead to fibrosis and scar formation. Can you comment on this?

Authors: Indeed, in the long run, the increased collagen formation may contribute to fibrosis and scarring. Because the present study assessed the incorporation of the scaffolds only in an early phase, *i.e.* 14 d after implantation, it is not possible to make a valid statement about the long-term performance of the implants. However, an early collagen formation was observed also within the pores of ad-MVF-seeded scaffolds and not only at their interface with

the surrounding host tissue. Hence, this pattern rather indicated an improved tissue ingrowth and implant incorporation, whereas a sole collagen formation around the implants would rather be a sign for scarring and scaffold fibrotic encapsulation over time.

Heiko Sorg: How do you explain the nearly explosive increase in perfused ROIs in Fig. 4 from day 3 nearly nothing to about 70-80 %?

Authors: This vascularisation pattern is typical for ad-MVF-seeded scaffolds. Due to their preserved vessel morphology, they rapidly reassemble *in vivo* into new microvascular networks. As soon as these networks also develop interconnections with the vessels of the surrounding host tissue, which typically occurs 3-6 d after implantation, they are completely blood-perfused within a short time. In contrast, scaffold vascularisation by angiogenic ingrowth of newly developing microvessels from the host microvasculature would be characterised by a slower but more uniform increase in perfused ROIs over time (Laschke *et al.*, 2010, additional reference).

Additional Reference

Laschke MW, Strohe A, Menger MD, Alini M, Eglin D (2010) *In vitro* and *in vivo* evaluation of a novel nanosize hydroxyapatite particles/poly(esterurethane) composite scaffold for bone tissue engineering. Acta Biomater **6**: 2020-2027.

. Laschke MW, Kleer S, Scheuer C, Eglin D, Alini M, Menger MD (2015) Pre-cultivation of adipose tissuederived microvascular fragments in porous scaffolds does not improve their *in vivo* vascularisation potential. Eur Cell Mater **29**: 190-200.

Editor's note: The Scientific Editor responsible for this paper was Juerg Gasser.

